Felty’s syndrome, insights and updates

Mohammad Bagher Owlia, Kam Newman, Mojtaba Akhtari

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Felty’s syndrome (FS) is characterized by the triad of seropositive rheumatoid arthritis (RA) with destructive joint involvement, splenomegaly and neutropenia. Current data shows that 1-3% of RA patients are complicated with FS with an estimated prevalence of 10 per 100,000 populations. The complete triad is not an absolute requirement, but persistent neutropenia with an absolute neutrophil count (ANC) generally less than 1500/mm3 is necessary for establishing the diagnosis. Felty’s syndrome may be asymptomatic but serious local or systemic infections may be the first clue to the diagnosis. FS is easily overlooked by parallel diagnoses of Sjӧgren syndrome or systemic lupus erythematosus or lymphohematopoietic malignancies. The role of genetic (HLA DR4) is more prominent in FS in comparison to classic rheumatoid arthritis. There is large body of evidence that in FS patients, both cellular and humoral immune systems participate in neutrophil activation, and apoptosis and its adherence to endothelial cells in the spleen. It has been demonstrated that proinflammatory cytokines may have inhibitory effects on bone marrow granulopoiesis. Binding of IgGs to neutrophil extracellular chromatin traps (NET) leading to neutrophil death plays a crucial role in its pathophysiology. In turn, "Netting" neutrophils may activate auto-reactive B cells leading to further antibody and immune complex formation. In this review we discuss on basic pathophysiology, epidemiology, genetics, clinical, laboratory and treatment updates of Felty’s syndrome

Original languageEnglish (US)
Pages (from-to)129-136
Number of pages8
JournalOpen Rheumatology Journal
Volume8
Issue number1
StatePublished - Jan 1 2015

Fingerprint

Felty Syndrome
Rheumatoid Arthritis
Neutrophils
Neutropenia
HLA-DR4 Antigen
Neutrophil Activation
Molecular Epidemiology
Splenomegaly
Antigen-Antibody Complex
Systemic Lupus Erythematosus
Chromatin
Immune System
B-Lymphocytes
Spleen
Endothelial Cells
Joints
Bone Marrow
Apoptosis
Cytokines
Antibodies

Keywords

  • Cytopenia
  • Felty’s syndrome
  • LGL syndrome
  • Neutropenia
  • Rheumatoid arthritis
  • Splenomegaly
  • Treatment

ASJC Scopus subject areas

  • Rheumatology

Cite this

Owlia, M. B., Newman, K., & Akhtari, M. (2015). Felty’s syndrome, insights and updates. Open Rheumatology Journal, 8(1), 129-136.

Felty’s syndrome, insights and updates. / Owlia, Mohammad Bagher; Newman, Kam; Akhtari, Mojtaba.

In: Open Rheumatology Journal, Vol. 8, No. 1, 01.01.2015, p. 129-136.

Research output: Contribution to journalArticle

Owlia, MB, Newman, K & Akhtari, M 2015, 'Felty’s syndrome, insights and updates', Open Rheumatology Journal, vol. 8, no. 1, pp. 129-136.
Owlia MB, Newman K, Akhtari M. Felty’s syndrome, insights and updates. Open Rheumatology Journal. 2015 Jan 1;8(1):129-136.
Owlia, Mohammad Bagher ; Newman, Kam ; Akhtari, Mojtaba. / Felty’s syndrome, insights and updates. In: Open Rheumatology Journal. 2015 ; Vol. 8, No. 1. pp. 129-136.
@article{a170a8e328c4465887a49fc9b5680aaa,
title = "Felty’s syndrome, insights and updates",
abstract = "Felty’s syndrome (FS) is characterized by the triad of seropositive rheumatoid arthritis (RA) with destructive joint involvement, splenomegaly and neutropenia. Current data shows that 1-3{\%} of RA patients are complicated with FS with an estimated prevalence of 10 per 100,000 populations. The complete triad is not an absolute requirement, but persistent neutropenia with an absolute neutrophil count (ANC) generally less than 1500/mm3 is necessary for establishing the diagnosis. Felty’s syndrome may be asymptomatic but serious local or systemic infections may be the first clue to the diagnosis. FS is easily overlooked by parallel diagnoses of Sjӧgren syndrome or systemic lupus erythematosus or lymphohematopoietic malignancies. The role of genetic (HLA DR4) is more prominent in FS in comparison to classic rheumatoid arthritis. There is large body of evidence that in FS patients, both cellular and humoral immune systems participate in neutrophil activation, and apoptosis and its adherence to endothelial cells in the spleen. It has been demonstrated that proinflammatory cytokines may have inhibitory effects on bone marrow granulopoiesis. Binding of IgGs to neutrophil extracellular chromatin traps (NET) leading to neutrophil death plays a crucial role in its pathophysiology. In turn, {"}Netting{"} neutrophils may activate auto-reactive B cells leading to further antibody and immune complex formation. In this review we discuss on basic pathophysiology, epidemiology, genetics, clinical, laboratory and treatment updates of Felty’s syndrome",
keywords = "Cytopenia, Felty’s syndrome, LGL syndrome, Neutropenia, Rheumatoid arthritis, Splenomegaly, Treatment",
author = "Owlia, {Mohammad Bagher} and Kam Newman and Mojtaba Akhtari",
year = "2015",
month = "1",
day = "1",
language = "English (US)",
volume = "8",
pages = "129--136",
journal = "Open Rheumatology Journal",
issn = "1874-3129",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

TY - JOUR

T1 - Felty’s syndrome, insights and updates

AU - Owlia, Mohammad Bagher

AU - Newman, Kam

AU - Akhtari, Mojtaba

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Felty’s syndrome (FS) is characterized by the triad of seropositive rheumatoid arthritis (RA) with destructive joint involvement, splenomegaly and neutropenia. Current data shows that 1-3% of RA patients are complicated with FS with an estimated prevalence of 10 per 100,000 populations. The complete triad is not an absolute requirement, but persistent neutropenia with an absolute neutrophil count (ANC) generally less than 1500/mm3 is necessary for establishing the diagnosis. Felty’s syndrome may be asymptomatic but serious local or systemic infections may be the first clue to the diagnosis. FS is easily overlooked by parallel diagnoses of Sjӧgren syndrome or systemic lupus erythematosus or lymphohematopoietic malignancies. The role of genetic (HLA DR4) is more prominent in FS in comparison to classic rheumatoid arthritis. There is large body of evidence that in FS patients, both cellular and humoral immune systems participate in neutrophil activation, and apoptosis and its adherence to endothelial cells in the spleen. It has been demonstrated that proinflammatory cytokines may have inhibitory effects on bone marrow granulopoiesis. Binding of IgGs to neutrophil extracellular chromatin traps (NET) leading to neutrophil death plays a crucial role in its pathophysiology. In turn, "Netting" neutrophils may activate auto-reactive B cells leading to further antibody and immune complex formation. In this review we discuss on basic pathophysiology, epidemiology, genetics, clinical, laboratory and treatment updates of Felty’s syndrome

AB - Felty’s syndrome (FS) is characterized by the triad of seropositive rheumatoid arthritis (RA) with destructive joint involvement, splenomegaly and neutropenia. Current data shows that 1-3% of RA patients are complicated with FS with an estimated prevalence of 10 per 100,000 populations. The complete triad is not an absolute requirement, but persistent neutropenia with an absolute neutrophil count (ANC) generally less than 1500/mm3 is necessary for establishing the diagnosis. Felty’s syndrome may be asymptomatic but serious local or systemic infections may be the first clue to the diagnosis. FS is easily overlooked by parallel diagnoses of Sjӧgren syndrome or systemic lupus erythematosus or lymphohematopoietic malignancies. The role of genetic (HLA DR4) is more prominent in FS in comparison to classic rheumatoid arthritis. There is large body of evidence that in FS patients, both cellular and humoral immune systems participate in neutrophil activation, and apoptosis and its adherence to endothelial cells in the spleen. It has been demonstrated that proinflammatory cytokines may have inhibitory effects on bone marrow granulopoiesis. Binding of IgGs to neutrophil extracellular chromatin traps (NET) leading to neutrophil death plays a crucial role in its pathophysiology. In turn, "Netting" neutrophils may activate auto-reactive B cells leading to further antibody and immune complex formation. In this review we discuss on basic pathophysiology, epidemiology, genetics, clinical, laboratory and treatment updates of Felty’s syndrome

KW - Cytopenia

KW - Felty’s syndrome

KW - LGL syndrome

KW - Neutropenia

KW - Rheumatoid arthritis

KW - Splenomegaly

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84923209522&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923209522&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84923209522

VL - 8

SP - 129

EP - 136

JO - Open Rheumatology Journal

JF - Open Rheumatology Journal

SN - 1874-3129

IS - 1

ER -